Featured

May 11 2022

CEO Update: Enveric to Spin-off and Dividend Cannabinoid Pipeline to Shareholders

By Enveric Featured

Dr. Joseph Tucker, CEO of Enveric Biosciences, details the Company’s plan to spin-off its #cannabinoid clinical development pipeline assets to a wholly-owned subsidiary, Acanna Therapeutics Inc. Following the spin-off, the…

May 11 2022

Love0

NASDAQ-Listed Enveric To Split Into Two Companies, One For Cannabinoids, One For Psychedelics

https://www.benzinga.com/markets/cannabis/22/05/27124788/exclusive-nasdaq-listed-enveric-to-split-into-two-companies-one-for-cannabinoids-one-for-psyched

Mar 31 2022

Love0

Bob Dagher, Chief Medical Officer at Enveric Biosciences [The Green Rush]

By Enveric Featured, In the News

https://www.enveric.com/wp-content/uploads/2022/03/Green_Rush_Enveric_FULL_SHOW.mp3

Sep 28 2021

Love0

The Psybrary™: Library of Novel Derivative Molecules Based on Classic Psychedelics

By Enveric Featured

Enveric is focused on creating a library of novel derivative molecules based on classic psychedelics.

Science

Investors

News & Media

Contact

Sign Up for Updates

Enveric Biosciences is a development stage company that markets no products at this time. The content of this site is not intended to be promotional or to suggest any product or use of a product that has been approved by any regulatory body.